Niagen Bioscience Inc
NAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.2% | 16% | 6.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 61.8% | 60.8% | 59.4% | 61.5% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 9.2% | -4.7% | -23.2% | -37.7% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 8.6% | -5.9% | -23% | -40.2% |
| EPS Diluted | 0.11 | -0.066 | -0.24 | -0.4 |
| % Growth | 266.9% | 72.5% | 40% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |